Figure 1
From: Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism
Therapy for HAE is directed at controlling the dysregulated activity of kallikrein and bradykinin that is responsible for the clinical symptoms of HAE. The hatched bar represents the inhibitory activity of C1INH, the orange bar the inhibitor activity of ecallantide, and the black × the receptor antagonism of icatibant. Source: Kaplan AP, Joseph K. The bra-dykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193-204.